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Abstract Background Prescribing errors in primary care
are problematic. The electronic prescription service (EPS)
is an English electronic system linking prescribing, dis-
pensing and reimbursement, designed to rectify some of the
problems associated with paper-based prescribing. Objec-
tive To document the numbers and types of interventions
made by community pharmacists and their staff using EPS
release 2 (EPSR2), compare these with those made for
other prescription types, and comment on potential effects
of EPSR2 on pharmacy practice. Methods We invited staff
in 15 community pharmacies to record problems encoun-
tered arising from failures in prescribing, dispensing or
supply systems for prescribed medication, for a 2 week
period. Results Eight pharmacies participated, of which
five used EPSR2. These pharmacies reported 69 problems
with 68 prescriptions (median 7.5 problems per pharmacy,
range 2–22). A total of 33 problems were clinical in nature
and 6 were organisational or logistical in origin. Thirty
unsigned prescriptions were reported, all non-EPSR2. Of
the 69 problems, eight were primarily related to EPSR2
functionality. Conclusion EPSR2 should reduce the num-
ber of unsigned prescriptions in circulation. However,
prescribers should avoid the use of Latin abbreviations that
cannot be interpreted directly by patients, and consider the
compatibility of regularly prescribed items with the NHS
dictionary of medicines and devices.
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Impact of findings on practice
• To reduce the numbers of unsigned prescriptions in the
UK, NHS prescribers in England should use the elec-
tronic prescription service release 2 (EPSR2) where
appropriate.
• The creation of split prescriptions, where some items are
prescribed electronically and some on paper, may cause
problems; a method of highlighting prescriptions that
are partly electronic and partly paper-based is needed.
• Since EPSR2 requires prescribed items to be compliant
with the NHS dictionary of medicines and devices
(DM ? D), prescribers should change non-DM ? D
items to DM ? D equivalents wherever possible to
avoid subsequent problems with EPSR2.
• Community pharmacy staff in the UK will need to
check the directions on EPSR2 prescriptions before
printing labels, and amend any that are not appropri-
ately phrased for patients.
Introduction
Prescribing errors occur in 4.0 % of drugs prescribed in
United Kingdom (UK) primary care [1]. Community
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pharmacists play a key role in identifying and rectifying such
errors, as well as resolving other problems such as unavail-
ability of prescribed medication [2, 3]. However, previous
UK studies have focussed on traditional paper prescriptions,
either computer generated or handwritten [2, 3].
The introduction of England’s electronic prescription
service release 1 (EPSR1) for primary care began in 2005.
EPSR1 prescriptions are standard paper prescriptions with
an additional barcode. When the barcode is scanned in the
community pharmacy, an electronic copy of the prescrip-
tion data is downloaded to the pharmacy computer to
populate the patient medication record and the labels for
dispensed items.
EPS release 2 (EPSR2) is now being introduced, with
the first sites having gone live in July 2009. EPSR2 is an
electronic system linking prescribing, dispensing and
reimbursement, designed to rectify some of the problems
associated with paper-based prescribing such as unsigned
prescriptions. Using EPSR2, electronic prescriptions are
digitally signed by the prescriber and the electronic pre-
scription transmitted to a nominated community pharmacy
of the patient’s choice. Patients are generally given a non-
essential printed ‘token’ in lieu of a prescription, while the
legal prescription is transmitted to the nominated pharmacy
via a central server, the NHS ‘Spine’ [4]. A barcode on the
token can be used to download the prescription at another
pharmacy if required. Only items in the UK NHS dictio-
nary of medicines and devices (DM ? D [5]) can be pre-
scribed using EPSR2, and schedule 2 and 3 controlled
drugs cannot be prescribed.
No study has yet explored the types of prescribing
errors identified or the interventions required by commu-
nity pharmacists working with EPSR2. It is also not yet
known whether EPSR2 will introduce new types of
problems which community pharmacists will need to be
aware of.
Aim of the study
We wanted to document the numbers and types of inter-
ventions made by community pharmacists working with
EPSR2, compare these with those arising from non-EPSR2
prescriptions, and to comment on potential effects of
EPSR2 on community pharmacy practice.
Methods
We invited all 15 community pharmacies, from five Eng-
lish primary care trusts, who were participating in a wider
evaluation of the EPSR2 system and for whom we already
had the appropriate permissions. At the time of data
collection, nine (60 %) were using EPSR2 (‘EPSR2 live’),
and six (40 %) were not (‘non-EPSR2 live’). As we were
limited in the number of pharmacies we could approach
and were asking pharmacy staff to record data, we incen-
tivised participation by offering a £100 high-street voucher
to participating pharmacy teams, supplied on completion.
We asked pharmacists to record information on all
problems arising from failures in prescribing, dispensing or
supply systems, in relation to prescribed medication, over a
2 week period. The feasibility of using such self-reported
data in community pharmacy has previously been demon-
strated [3, 6, 7]. We designed a data collection form for
community pharmacy staff to complete, piloted this and
then used the feedback to produce a final data collection
booklet. This presented the study objectives, instructions
for staff and 36 forms (Sect. Appendix). One of the
research team briefed participating pharmacists on the
project’s purpose, how to complete the data collection
booklet and addressed any queries; we asked pharmacists
to brief locum pharmacists and other staff members as
needed. We asked participants to record brief descriptions
as soon as possible after identifying prescription-related
problems that needed resolving to dispense the prescrip-
tion, indicating how they were resolved, and whether the
prescription was EPSR1, EPSR2, or non-EPS (either hand-
written or computer generated). We also requested details
of the number of items dispensed over the study period.
Data were analysed descriptively. We classified recorded
problems in three ways. First, we categorised the type of
problem into one of 13 mutually exclusive categories
(Table 1). Second, the origin of the problem was categorised
as being of a legal, clinical, or an organisational/logistical
nature. Finally, any problems primarily related to EPS func-
tionality were classified as being either EPSR1- or EPSR2-
specific. Each prescribed item could be associated with mul-
tiple problems. Classifications were discussed by the research
team and agreed by consensus. Where we had data on the
number of items dispensed during the study period, the
prevalence of problems was calculated for each pharmacy.
This work was conducted as part of a larger evaluation
of the EPSR2 system which was classed as a service
evaluation; ethics approval was not required.
Results
Of the 15 pharmacies invited to participate, one provided
only pilot data, and six did not return any data. Analysis
was therefore based on eight (53 %) pharmacies, of which
five were EPSR2-live (Table 2).
Staff in these eight pharmacies reported a total of 69
problems with 68 prescriptions over the 2 week study per-
iod (median 7.5 problems per pharmacy, range 2-22). Types
Int J Clin Pharm (2013) 35:1030–1035 1031
123
of problem are shown in Table 1. In relation to the origin of
each problem, 30 (43 %) were problems with the legal
aspects of the prescription; these all related to unsigned
non-EPS and EPSR1 prescriptions. A further 33 (48 %)
were clinical in nature. Potentially serious clinical errors
included a prescription for an incorrect insulin pen (incor-
rect formulation) and a prescription for both erythromycin
and simvastatin (drug–drug interaction). The remaining six
(9 %) arose due to organisational or logistical problems.
One, an EPSR1-specific problem, arose when a doctor
mistakenly reprinted a copy of a previously dispensed
prescription rather than creating a new one. Another two
were EPSR2 prescriptions where the pharmacy had been
incorrectly nominated. Manufacturing delays and pre-
scription print-quality problems were also reported.
Five pharmacies reported the number of items dispensed
during the study period, for these pharmacies the individual
problem reporting rate ranged from 0.19 to 0.69 % (1.9–6.9
problems per 1,000 items dispensed) giving an overall rate
of 0.58 % (69 problems in 11,850 dispensed items). The
two EPSR2 live pharmacies reported 21 problems in 4,094
dispensed items (0.51 %), and three non-EPSR2 live
pharmacies reported 31 problems in 7,756 items (0.40 %).
Overall, eight problems (12 %) were judged to have
been caused specifically by the EPSR2 system, and one
(1 %) due to EPSR1. Specifically, we identified four cases,
all at the same pharmacy, of incomplete EPSR2 prescrip-
tions with no dose visible on the screen; the dose was
printed on the dispensing token and therefore manually
entered by the pharmacist. Some prescribers used Latin
abbreviations, which we classed as ‘incorrect instructions’.
With EPSR2 these were transferred automatically to the
dispensing label and had to be amended manually by
pharmacy staff. For example ‘‘QDSPRN’’ had to be
amended to ‘‘Four times a day when required’’. Two
missing prescriptions were caused by community phar-
macy nominations which had been incorrectly set up. The
final problem involved a missing prescription: a patient
Table 1 Interventions reported
Classification Number (%) of problems Origin of problem Prescription type
Clinical Legal Organisational Non-EPS EPSR1 EPSR2
Unsigned 30 (43 %) 0 30 0 19 11 0
Incomplete prescription 6 (9 %) 6 0 0 2 0 4
Missing prescription 5 (7 %) 2 0 3 2 1 2
Drug-drug interaction 4 (6 %) 4 0 0 3 1 0
Incorrect formulation 4 (6 %) 4 0 0 3 0 1
Incorrect drug 4 (6 %) 4 0 0 4 0 0
Incorrect quantity 4 (6 %) 4 0 0 3 1 0
Supply problem 3 (4 %) 0 0 3 0 1 2
Missing item 2 (3 %) 2 0 0 2 0 0
Incorrect dose 2 (3 %) 2 0 0 2 0 0
Duplicate drug 2 (3 %) 2 0 0 0 2 0
Incorrect instructions 2 (3 %) 2 0 0 1 0 1
Illegible prescription 1 (1 %) 1 0 0 1 0 0
Total (% of all problems) 69 (100 %) 33 (48 %) 30 (43 %) 6 (9 %) 42 (61 %) 17 (25 %) 10 (14 %)
Table 2 Details and workload of participating pharmacies
Pharmacy
number
Location Number of days’
data collection
Number non-EPS
dispensed items
Number of EPSR1
dispensed items
Number of EPSR2
dispensed items
Total number of
items dispensed
37 Village high street 14 290 2,889 Not EPSR2 live 3,179
38 City—suburban Not reported Not reported Not reported Not EPSR2 live 3,709
39 Town shopping centre 14 Not Reported Not reported Not EPSR2 live 868
46 Inner city 14 418 1,254 140 1,812
48 Inner city 11 1,133 812 337 2,282
49 Town high street 14 Not reported Not reported Not reported Not reported
50 Town high street 8 Not reported 606 311 Not reported
51 Inner city 14 Not reported Not reported Not reported Not reported
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arrived at the pharmacy having been told that their pre-
scription had been transmitted electronically but the phar-
macy staff had not received it. The GP surgery was called
and it transpired that a paper prescription had in fact been
issued, which was subsequently faxed to the pharmacy.
Discussion
The results of this study indicate that in line with previous
work [3], circulation of unsigned paper prescriptions
remains problematic, creating extra work for pharmacy and
GP staff, as well as inconveniencing patients. EPSR2
prescriptions are digitally signed before transmission, thus
eliminating this problem.
Problems specific to EPSR2 were also identified. One
example of miscommunication resulted in a patient
appearing at a pharmacy expecting an EPSR2 prescription,
when their prescription was on paper and waiting at the GP
surgery. This type of problem is likely to be problematic
especially during EPSR2 roll-out, and may be exacerbated
when a patient’s medication is partly prescribed electroni-
cally and partly on paper (for example if any non DM ? D
items or controlled drugs are required). We also identified
new problems caused by prescribers’ instructions appearing
automatically on the label directions. Traditionally,
instructions on a prescription are interpreted and transcribed
onto the medicine’s label by pharmacy staff, using wording
appropriate for the patient. The EPSR2 system can auto-
matically transfer prescribers’ dosage instructions onto the
medication label without pharmacy staff actively entering
them. The extra input needed by community pharmacy staff
to manually edit prescribers’ instructions may somewhat
negate time savings envisaged through instructions being
transferred automatically onto the label. Community phar-
macies and their local GPs need to jointly establish common
instruction templates for use on patient labels in order to
fully realise the time-saving potential of EPSR2.
Our problem reporting rates are in line with similar
studies [3, 8] but lower than that reported using more
intensive data collection methods [9].
Implications for practice
Electronic prescription service release 2 (EPSR2) is likely to
result in a decreased proportion of prescriptions arriving
unsigned at community pharmacies, thus reducing unplan-
ned workload for pharmacy and GP staff, and patient
inconvenience. Problems were reported which were caused
by prescribed items not being on DM ? D; steps should be
taken to ensure that all items on EPSR2 are DM ? D-com-
pliant. The use of both paper and electronic prescriptions for
the same patient has the potential to be problematic; a system
which highlights the presence of additional non-EPSR2
prescriptions for EPSR2 patients should be investigated.
GPs, pharmacists and software developers should work
together to find solutions to problems such as the enduring
use of abbreviations within an electronic system.
Strengths and limitations
This exploratory study is the first to look at problematic
prescriptions in pharmacies using EPSR2. Limitations
include the apparent mixed engagement of pharmacies in
data collection which reduces the generalisability of the
findings, and that only some pharmacies provided data on the
number of dispensed items during the study period, limiting
our ability to calculate problem prevalence rates; we suggest
that future studies incorporate researchers periodically con-
tacting participating pharmacies to increase engagement and
to identify and resolve any barriers to ongoing participation.
Future studies should establish the numbers of dispensed
items, broken down by EPSR1, EPSR2 and non-EPS items,
and use a larger sample size, in order to investigate differ-
ences in problem rates between the different types of pre-
scription and whether other pharmacy-related factors and/or
inter-pharmacist variability affect the problem rates docu-
mented. Finally, we did not formally assess the clinical
significance of the problems identified.
Conclusion
Electronic prescription service release 2 (EPSR2) has the
potential to reduce the number of unsigned prescriptions
received at pharmacies. However, prescribers should avoid
the use of Latin abbreviations that cannot be interpreted
directly by the patients, and consider the compatibility of
regularly prescribed items with DM ? D. Further work is
needed to explore the causes of other types of problem
identified and how they can be resolved before we can
draw clear conclusions regarding the impact of EPSR2.
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